Helen Hobbs Net Worth

Helen Hobbs biography

Dr. Helen H. Hobbs M.D. serves as Independent Director of the Company. Elected to the National Academy of Medicine in 2004, the American Academy of Arts and Sciences in 2006, and the National Academy of Sciences in 2007. Received both the Clinical Research Prize (2005) and Distinguished Scientist Award (2007) from the American Heart Association. In 2012, received the inaugural International Society of Atherosclerosis Prize. Received the Pearl Meister Greengard Award (2015) and the Breakthrough Prize in Life Sciences (2015); the Passano Award (2016); the Harrington Prize for Innovation in Medicine (2018); the Lefoulon-Delalande Grand Prize in Science (2018); the Gerald D. Aurbach Award for Outstanding Translational Research (2019); and the Anitschkow Prize (2019). Dr. Hobbs’ background reflects significant achievements in academia and medicine. She has served as a faculty member at the University of Texas Southwestern Medical Center for more than 30 years and is a leading geneticist in liver and heart disease, areas in which Pfizer has significant investments and experience. Pfizer benefits from her experience, expertise, achievements and recognition in both medicine and science.

What is the salary of Helen Hobbs?

As the Independent Director of Pfizer, the total compensation of Helen Hobbs at Pfizer is $383,600. There are 11 executives at Pfizer getting paid more, with Albert Bourla having the highest compensation of $17,929,000.

What's Helen Hobbs's mailing address?

Helen's mailing address filed with the SEC is 66 HUDSON BOULEVARD EAST, ATTN: CORPORATE SECRETARY, NEW YORK, NY, 10001-2192.

Insiders trading at Pfizer

Over the last 12 years, insiders at Pfizer have traded over $216,003,942 worth of Pfizer stock and bought 24,324 units worth $872,198 . The most active insiders traders include Shantanu Narayen, Ian C Read, and James M Kilts. On average, Pfizer executives and independent directors trade stock every 12 days with the average trade being worth of $2,169,896. The most recent stock trade was executed by Jennifer B. Damico on 13 August 2024, trading 5,154 units of PFE stock currently worth $147,714.

What does Pfizer do?

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered at The Spiral in Manhattan, New York City. The company was established in 1849 in New York by two German entrepreneurs, Charles Pfizer and his cousin Charles F. Erhart.

Pfizer executives and stock owners

Pfizer executives and other stock owners filed with the SEC include:

• Albert Bourla,
  Chairman of the Board, Chief Executive Officer
• Frank D'Amelio,
  Chief Financial Officer, Executive Vice President - Business Operations and Global Supply
• Mikael Dolsten,
  Chief Scientific Officer, President - Worldwide Research, Development and Medical
• John Young,
  Chief Business Officer, Group President
• Dr. Albert Bourla D.V.M., DVM, Ph.D.,
  Chairman & CEO
• Frank A. D'Amelio,
  CFO & Exec. VP
• Dr. Mikael Dolsten M.D., Ph.D.,
  Chief Scientific Officer and Pres of Worldwide Research, Devel. & Medical
• Angela Hwang,
  Group Pres of Biopharmaceuticals Group
• John D. Young,
  Advisor
• Shantanu Narayen,
  Lead Independent Director
• Wyllie Don Cornwell,
  Independent Director
• Helen Hobbs,
  Independent Director
• Suzanne Nora Johnson,
  Independent Director
• Joseph Echevarria,
  Independent Director
• James Kilts,
  Independent Director
• Ronald Blaylock,
  Independent Director
• Dan Littman,
  Independent Director
• Scott Gottlieb,
  Independent Director
• James Quincey,
  Independent Director
• Susan Hockfield,
  Independent Director
• Susan Desmond-Hellmann,
  Director
• Gordon Loh,
  Senior Vice President, Corporate Audit
• Jennifer Damico,
  Senior Vice President, Principal Accounting Officer, Controller
• Sally Susman,
  Chief Corporate Affairs Officer, Executive Vice President
• Alexander Mackenzie,
  Executive Vice President, Chief Development Officer
• Douglas Lankler,
  Executive Vice President, General Counsel
• Rady Johnson,
  Chief Compliance, Quality and Risk Officer, Executive Vice President
• Lidia Fonseca,
  Executive Vice President, Chief Technology Officer and Digital Officer
• Dawn Rogers,
  Chief Human Resource Officer, Executive Vice President
• Angela Hwang,
  Group President, Pfizer Biopharmaceuticals Group
• Rady A. Johnson,
  Exec. VP and Chief Compliance, Quality & Risk Officer
• Douglas M. Lankler,
  Exec. VP & Gen. Counsel
• Christopher J. Stevo CFA,
  Sr. VP & Chief Investor Relations Officer
• Lidia L. Fonseca,
  Exec. VP and Chief Digital & Technology Officer
• Jennifer B. Damico,
  Sr. VP, Controller & Principal Accounting Officer
• Mike McDermott,
  Chief Financial Officer
• William Pao,
  Executive Vice President
• Stephen W Sanger,
  Director
• Frances D Fergusson,
  Director
• James C Smith,
  Director
• Laurie J Olson,
  Executive Vice President
• W Don Cornwell,
  Director
• Loretta V Cangialosi,
  Sr. Vice President, Controller
• Charles H Hill,
  Executive Vice President
• Dennis A Ausiello,
  Director
• Kirsten Lund Jurgensen,
  Executive Vice President
• Ian C Read,
  Chairman & CEO
• Freda C Lewis Hall,
  Executive Vice President
• Aamir Malik,
  Executive Vice President
• Christoffel Boshoff,
  Executive Vice President
• Michael Goettler,
  Group President
• Cyrus Taraporevala,
  Director
• Iii William H Gray,
  Director
• M Anthony Burns,
  Director
• Cavan M. Redmond,
  Group President
• Kristin C Peck,
  Executive Vice President
• David S Simmons,
  Business Unit President
• Geno J Germano,
  Business Unit President
• Anthony J Maddaluna,
  Executive Vice President
• Olivier Brandicourt,
  Business Unit President
• Marc Tessier Lavigne,
  Director
• George A Lorch,
  Director
• Amy W Schulman,
  Executive Vice President
• Constance J Horner,
  Director
• Payal Sahni,
  Executive Vice President
• William R Jr Carapezzi,
  Executive Vice President
• Michael Mc Dermott,
  Executive Vice President
• David M Denton,
  Chief Financial Officer & EVP